Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 ARI-0001 (varnimcabtagene autoleucel) in relapsed/refractory CD19+ ALL
2024-513601-31-00Phase 2Authorised
- Sponsor
- IDIBAPS
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI-0001 in acute lymphoblastic leukemia (ALL), sponsored by IDIBAPS. Primary endpoint: MRD-negative response rate at day 28. Planned start May 2024; status: authorised.
02
Drugs
ARI-0001
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-513601-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513601-31-00.